Edition:
India

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

4.04USD
2:29am IST
Change (% chg)

$0.07 (+1.76%)
Prev Close
$3.97
Open
$3.98
Day's High
$4.11
Day's Low
$3.98
Volume
399,029
Avg. Vol
300,637
52-wk High
$4.47
52-wk Low
$2.81

Select another date:

Wed, Jan 17 2018

BRIEF-Amarin Announces Commencement Of Vascepa Clinical Development In Mainland China

* AMARIN ANNOUNCES COMMENCEMENT OF VASCEPA CLINICAL DEVELOPMENT IN MAINLAND CHINA Source text for Eikon: Further company coverage:

BRIEF-Amarin Corp Sees Full-Year 2017 Net Product Revenue Estimated Between $177 Mln-$180 Mln​

* AMARIN PROVIDES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 OUTLOOK

BRIEF-Amarin Says It Is On Track To Report Top-Line Results From REDUCE-IT Cardiovascular Outcomes Study

* AMARIN ANNOUNCES REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY FINAL PATIENT VISITS TO COMMENCE IN MARCH 2018

BRIEF-Amarin reports Q3 loss per share $0.04

* Amarin reports third quarter 2017 financial results and provides update on operations

BRIEF-Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

* Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

BRIEF-Amarin names Mark Salyer chief commercial officer

* Amarin appoints Mark W. Salyer to new position of chief commercial officer

BRIEF-Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned

* Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee

BRIEF-Amarin reports Q2 loss per share $0.05

* Amarin reports second quarter 2017 financial results and provides update on operations

Select another date: